The absorption of
levodopa can be reduced by 30 to 50% by
ferrous sulfate due to
levodopa chelation. Therefore all
iron compounds are expected to act similarly. Carbidopa levels are also reduced. There is some evidence that this interaction causes a decrease in symptom
control.
Separating the
administration of the
iron as much as possible is likely to be an effective way of managing this interaction.